application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than May 1, 1995.

A. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. Buerge Bancshares, Inc., Joplin, Missouri; to acquire 100 percent of the voting shares of Peoples State Bank, Claremore, Oklahoma.

Board of Governors of the Federal Reserve System, March 31, 1995.

Barbara R. Lowrey,

Associate Secretary of the Board.

[FR Doc. 95–8407 Filed 4–5–95; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES ADMINISTRATION

Public Buildings Service; Proposed Port of Entry, Located at Pacific Highway, Blaine, Whatcom County, WA; Notice of Availability for a Draft Environmental Impact Statement

The general Services Administration (GSA) hereby gives notice a Draft Environmental Impact Statement (DEIS) has been prepared in accordance with the National Environmental Policy Act (NEPA) of 1969, as amended. The DEIS was prepared for the proposed expansion of the Port of Entry located at Pacific Highway, Blaine, Whatcom County, Washington. The DEIS is being made available March 31, 1995. GSA is the lead Federal agency for the preparation of the EIS. The DEIS evaluates the proposed action, the no-action, and three (3) design alternatives.

Written comments should be as specific as possible and may address the adequacy of the EIS, the merits of the alternatives discussed, the impacts identified, and/or mitigation measures recommended and be sent no later than May 15, 1995 to GSA's EIS subconsultant, Berger/ABAM, at the following address: 33301 Ninth Avenue South, Federal Way, WA 98003.

Comments will also be accepted at a public meeting to be held on April 19, 1995, at the Blaine Senior Center, 763 ''G'' Street, Blaine, Washington 98230. The meeting will be held from 5:30 p.m. to 7:30 p.m.

Representatives of GSA and Berger/ABAM will receive comments from interested parties regarding the proposed project, the environmental analysis, and proposed mitigation measures. All comments received will be made a part of the administrative record for the DEIS and will be evaluated as part of the Final EIS review process.

For further information contact Donna M. Meyer, Regional Environmental Program Officer, General Services Administration, Public Buildings Service (10PL), 400 15th Street SW., Auburn, Washington 98001–6599, or at (206) 931–7675.

Dated: March 24, 1995.

L. Jay Pearson,

Regional Administrator (10A).

[FR Doc. 95–8414 Filed 4–5–95; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the ''Schedule of Certified Interest Rates with Range of Maturities.'' This rate may be revised quarterly by the Department of Health and Human Services in the **Federal Register**.

The Secretary of the Treasury has certified a rate of 14⅛ percent for the quarter ended March 31, 1995. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: March 30, 1995.

George Strader,

Deputy Assistant Secretary, Finance.

[FR Doc. 95–8397 Filed 4–5–95; 8:45 am]

BILLING CODE 4150–04–M

Food and Drug Administration

[Docket No. 95N–0082]

Animal Drug Export; Deslorelin Acetate Implant

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Peptide Technology Ltd. has filed an application requesting approval for the export of the animal drug Ovuplant™ (deslorelin acetate) to Canada.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Gregory S. Gates, Center for Veterinary Medicine (HFV–114), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1617.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Peptide Technology Ltd., 4–10 Inman Rd., Dee Why 2099, Australia, has filed application number 8019 requesting approval for the export of the animal drug Ovuplant™ (2.1 milligrams of deslorelin per implant, as the acetate) to Canada. The drug is a subcutaneous implant providing sustained release of a gonadotropin releasing hormone analog. It is indicated for inducing ovulation in the oestrus mare. The application was received and filed in the Center for Veterinary Medicine on March 20, 1995,